VEC.L Share News (VEC)

VEC.L Information

There is currently no data for VEC

Drug trials using Vectura's Fox nebuliser make progress

Tue, 03rd May 2016 14:21

(ShareCast News) - A respiratory treatment being developed using Vectura's Fox nebuliser technology device has passed safety and efficacy trials and looks likely to be moved into a Phase II efficacy study in infants.Drug developer Ablynx has published positive results from first-in-infant Phase I/IIa study of its inhaled ALX-0171 nanobody to treat 53 infants who had been hospitalised by a respiratory syncytial virus (RSV) infection.The trial hit its target of demonstrating favourable safety and tolerability profile when administered daily by inhalation in the target infant population using the FTSE 250 company's Fox nebuliser, with no serious adverse events reported due to the treatment.A hand-held battery-powered inhalation system, the Fox device delivers nebulised liquid drugs using a vibrating mesh technology that is proprietary to Vectura and which times the flow of an aerosolised drug immediately after the patient has inhaled.RSV is a very common virus that leads to cold-like symptoms in adults and older healthy children but can be more serious in infants, especially those in certain high-risk groups.Ablynx also said its nanobody was detected in the serum of RSV subjects after treatment, indicating it had been absorbed in the lungs, while anti-drug antibodies had no effect on the passage of the drug through the body and no adverse events were seen.Treatment with the inhaled drug was found to have an immediate impact on viral replication and also reduced viral load, as compared to placebo.Analysis of a composite of clinical efficacy endpoints led to an encouraging initial indication of a therapeutic effect for infants treated with ALX-0171.Vectura chief executive James Ward-Lilley said the results and the additional marked antiviral effect in RSV-infected infants was a positive step that "Ablynx believes support advancement into a Phase II efficacy study in infants".He added: "This progress is a further example of how Vectura continues to a partner of choice for the application of novel formulation and device technologies in the development of medicines."Shares in Vectura, which hit an all-time high of 188.5p in January, were up 0.7% to 173.2p by mid afternoon on Tuesday.

More News

19 Apr 2018 12:53

hVIVO CEO Steps Down In Favour Of Executive Chair As Loss Narrows

LONDON (Alliance News) - Clinical development and drug discovery business hVIVO PLC said Thursday its loss narrowed in 2017 as Chief Executive Kym Denny stepped aside for Executive Chairman Trevor

3 Apr 2018 08:41

EUROPE RESEARCH ROUNDUP-Aevis Victoria, Martela Oyj, Mediaset

April 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Aevis Victoria, Martela Oyj and Mediaset, on Tuesday. HIGHLIGHTS * Aevis SA

23 Mar 2018 18:23

DIRECTOR DEALINGS: Vectura Non-Executive Juliet Thompson Buys Shares

LONDON (Alliance News) - Vectura Group PLC said Friday Non-Executive Director Juliet Thompson bought shares worth GBP36,284 in the pharmaceutical company after

22 Mar 2018 16:16

DIRECTOR DEALINGS: Vectura Chairman, Non-Exec Director Buy Shares

LONDON (Alliance News) - Vectura Group PLC said on Thursday that two directors bought shares in the company on Wednesday.Chairman Bruno Angelici purchased 75,000 shares

21 Mar 2018 08:52

Vectura Delivers "Good" 2017 Results Despite Advair Disappointment

LONDON (Alliance News) - Pharmaceutical firm Vectura Group PLC said Wednesday it delivered a "good" set of 2017 results with underlying profit and revenue growth to

21 Mar 2018 08:31

UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 (Reuters) - British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma for

21 Mar 2018 07:47

UPDATE 1-UK Stocks-Factors to watch on March 21

March 21 (Reuters) - Britain's FTSE 100 index is seen opening up 13 points on Wednesday, according to financial bookmakers, with futures 0.26 pct higher ahead of the cash

21 Mar 2018 07:40

Drugmaker Vectura's 2017 revenue rises 17.2 pct

March 21 (Reuters) - British drugmaker Vectura reported a 17.2 percent rise in 2017 revenue on Wednesday, aided by higher demand for its asthma products Flutiform and Ultibro. The company,

20 Mar 2018 13:21

Legal & General Increases Vectura Stake To 3.7% From Below 3% (ALLISS)

LONDON (Alliance News) - Vectura Group PLC said Tuesday FTSE 100-listed insurer and asset manager Legal & General Group PLC increased its stake in the pharmaceutical firm

14 Mar 2018 16:20

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 15 March Old MutualFull Year ResultsPhoenix GroupFull Year GroupFull 16

12 Mar 2018 10:43

WINNERS & LOSERS SUMMARY: Vectura And Hikma Hurt By US FDA Ruling

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------easyJet, up 2.3% at on

12 Mar 2018 09:43

FTSE 100 lags Europe on miners and energy, Just Eat goes cold

(For a live blog on European stocks, type LIVE/ in an Eikon news window) * FTSE 100 up 0.1 pct * Just Eat hit by DB downgrade * Vectura, Hikma hit by delay to Advair GKN up 12

16 Feb 2017 07:49

Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal

16 Feb 2017 07:06

Vectura's GSK royalties agreements firing on all cylinders

(ShareCast News) - Vectura Group hit its royalty cap on sales of GlaxoSmithKline´s Ellipta range of products in 2016, one year ahead of forecasts. The cap was equivalent to £9.0m. The inhaled airways disease-focused business was also set to record £5.4m of 2016 revenues under a separate single digi

8 Feb 2017 13:49

UPDATE 1-Weak pound buoys GSK but drugmaker warns on 2017 generic threat

* 2017 core EPS seen flat-lower if mid-year generic Advair * Current exchange rates would lift 2017 sterling EPS 9 pct * Q4 2016 core EPS 26.1 pence vs consensus forecast 25.0p (Adds CEO comments, shares, background on new CEO) By Ben Hirschler LONDON, Feb 8 (Reuters) -

Latest Share Chat

VEC.L Share News (VEC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Drug trials using Vectura's Fox nebuliser make progress

Login to your account

Quickpicks are a member only feature

Login to your account